- 米国企業
- Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc.AMRX
| 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 |
|---|
| Net revenue | 1,663 | 1,626 | 1,993 | 2,094 | 2,212 |
|---|
| Cost of goods sold | 947 | 1,147 | 1,330 | 1,302 | 1,416 |
|---|
| Cost of goods sold impairment charges | - | 126 | 35 | 23 | 11 |
|---|
| Gross profit | 716 | 353 | 628 | 769 | 785 |
|---|
| Selling, general and administrative | 230 | 290 | 327 | 366 | 400 |
|---|
| Research and development | 194 | 188 | 180 | 202 | 196 |
|---|
| Asset Impairment Charges | 39 | 47 | 3 | 1 | 13 |
|---|
| Royalty Expense | - | 14 | 11 | 8 | 4 |
|---|
| Acquisition, transaction-related and integration expenses | 222 | 16 | 9 | 8 | 1 |
|---|
| Restructuring Charges | 56 | 34 | 2 | 2 | 1 |
|---|
| Change in fair value of contingent consideration | - | - | - | - | -1 |
|---|
| (Insurance recoveries) charges for property losses and associated expenses, net | - | - | - | - | -2 |
|---|
| Charges related to legal matters, net | 22 | -12 | -6 | -25 | -270 |
|---|
| Other operating income | - | - | - | - | 4 |
|---|
| Operating (loss) income | -20 | -249 | 91 | 153 | -95 |
|---|
| Interest expense, net | -144 | -168 | -146 | -136 | -158 |
|---|
| Foreign exchange (loss) gain, net | -20 | -5 | 16 | -0 | -12 |
|---|
| Gain (Loss) on Extinguishment of Debt | -20 | - | - | - | -0 |
|---|
| Gain on sale of international businesses | -3 | 7 | 0 | - | - |
|---|
| Other income, net | 3 | 1 | 3 | 15 | 18 |
|---|
| Total other expense, net | -183 | 28 | -127 | -121 | -153 |
|---|
| (Loss) income before income taxes | -203 | -220 | -36 | 31 | -248 |
|---|
| Income Tax Expense (Benefit) | -1 | 383 | -104 | 11 | 7 |
|---|
| Net (loss) income | -201 | -604 | 69 | 20 | -255 |
|---|
| Less: Net loss (income) attributable to non-controlling interests | -33 | -242 | -22 | 10 | -125 |
|---|
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest | - | - | - | - | -130 |
|---|
| Accretion of redeemable non-controlling interest | 1 | - | - | - | 0 |
|---|
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. | -21 | -362 | 91 | 11 | -130 |
|---|
| Earnings Per Share, Basic | - | - | 0.62 | 0.07 | -0.86 |
|---|
| Earnings Per Share, Diluted | - | - | 0.61 | 0.07 | -0.86 |
|---|